C12N 2760/20141
Use of virus, viral particle or viral elements as a vector
C12N2760/20141 (Use of virus, viral particle or viral elements as a vector) appears on 27 US grants and 46 published applications in this corpus.
Search patents in C12N- Granted patents
- 27
- Published applications
- 46
- Assignees
- 37
- Inventors
- 75
- Latest grant
- 8 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 2 |
| 2004 | 1 | 1 |
| 2005 | 0 | 1 |
| 2006 | 2 | 1 |
| 2007 | 0 | 1 |
| 2008 | 1 | 2 |
| 2009 | 1 | 1 |
| 2010 | 0 | 1 |
| 2011 | 2 | 4 |
| 2012 | 0 | 0 |
| 2013 | 1 | 2 |
| 2014 | 1 | 1 |
| 2015 | 1 | 1 |
| 2016 | 1 | 3 |
| 2017 | 1 | 0 |
| 2018 | 1 | 1 |
| 2019 | 1 | 1 |
| 2020 | 1 | 2 |
| 2021 | 2 | 4 |
| 2022 | 2 | 2 |
| 2023 | 3 | 7 |
| 2024 | 2 | 4 |
| 2025 | 2 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/20143Viral genome or elements thereof as genetic vectorIndexing code23
- C12N 2760/20145Special targeting system for viral vectorsIndexing code5
- C12N 2760/20142Virus or viral particle as vehicleIndexing code0
- C12N 2760/20144Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
Recent patents
- Multivalent vaccines for rabies virus and coronaviruses8 Apr 2025US 12,269,155 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Self-inactivating rabies virus vector encoding a nucleoprotein and degron21 Jan 2025US 12,203,092 B2Mironid Limited
- Coronavirus disease (COVID-19) vaccine7 May 2024US 11,975,067 B2Thomas Jefferson University
- RNA-based delivery systems with levels of control2 Apr 2024US 11,946,066 B2California Institute of Technology
- Apparatus for releasably holding a socket28 Nov 2023US 11,826,895 B2
- Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells of the peripheral nervous system27 Aug 2026US 2026/0248957 A1Turn Biotechnologies, Inc.
- A therapeutic against crimean-congo hemorrhagic fever virus6 Feb 2025US 2025/0041398 A1Thomas Jefferson University
- Chimeric pseudotyped recombinant rabies virus3 Oct 2024US 2024/0327802 A1Beam Therapeutics Inc.
- Adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulations18 Jul 2024US 2024/0238411 A1Bharat Biotech International Limited
- Compositions of glycoprotein particles27 Jun 2024US 2024/0207196 A1Scribe Therapeutics Inc.
Most cited
By later US patents
- Recombinant infectious non-segmented negative strand RNA virus156US 6,033,886 A2000
- Apparatus for releasably holding a socket11US 11,091,778 B22021
- Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife5US 7,074,413 B2Thomas Jefferson University · 2006
- Rhabdoviruses with reengineered coats5US 7,081,243 B1Yale University · 2006
- Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS3US 6,706,523 B2University of Georgia Research Foundation, Inc. · 2004